24/3/2014

WSJ INDIA WSJ LIVE MARKETWATCH BARRON'S Portfolio

India Rejects Bayer's Nexavar Plea - WSJ.com

DJX MORE

News, Quotes, Companies, Videos

SEARCH

Subscribe

Log In

BUSINESS

Dow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visit www.djreprints.com See a sample reprint in PDF format. Order a reprint of this article now

TOP STORIES IN BUSINESS

1 of 12

2 of 12

3 of 12

4 of 12

The Secret About Online Ad Traffic

Novartis Chairman Stresses R&D

Nokia, Microsoft Deal Delayed

Apple, Comcast Discuss StreamingTV Ser...

ASIAN BUSINESS NEWS

India Appeals Body Rejects Bayer's Plea on Nexavar

Email Print Sav e 0 Comments

By R U MMAN AH MED
Updated March 4, 2013 11:17 a.m. ET

CHENNAIIndia's patent appeals body Monday rejected Bayer AG BAYN.XE -2.11% 's plea to stop a local company from manufacturing and selling a generic version of its cancer drug Nexavar, a ruling that has wider implications for multinational drug makers operating in the South Asian nation. The German company last year approached the Intellectual Property Appellate Board after the local patent authority granted a "compulsory license" to Natco Pharma Ltd. 524816.BY -0.12% to manufacture a generic version of the drug. The Indian Controller General of Patents, Designs and Trademarks allowed Natco to make copies of the liver- and kidney-cancer drug on the grounds that Nexavar was too expensive for most people in India. The license allowed Natco to sell a generic version at less than one-30th of Bayer's price. India's patent law allows authorities to order holders of drug patents to license their products for local manufacturing if they are priced beyond the reach of patients. The patent authority's March 2012 order on Nexavar represented the first instance of a compulsory license being granted in the country. India says there is a need to balance intellectual property rights with the rights of people to get access to new and expensive medicines. Foreign producers argue India is discouraging innovation by weakening patents, reducing the incentive for big companies to invest time and money to discover drugs. The appellate board, which is based in the southern city of Chennai, said the patent authority was right in allowing a compulsory license for Nexavar as Bayer hadn't priced the drug at "reasonably affordable" rates. Bayer said it "strongly disagrees" with the conclusions of the appellate board and will pursue the case at the high court in Mumbai. The order "weakens the international patent system and endangers pharmaceutical research," the company said in a statement. Natco welcomed the order. "This is a reasoned and detailed order that can be sustained in any court of law," said M. Adinarayana, Natco's company secretary. The appeals body's ruling Monday could set a precedent for similar cases. "It will pave the way for future [compulsory] licenses, given that many of these [patented] drugs are exorbitantly priced" and aren't affordable for most people in India, said Shamnad Basheer, professor of IP Law at the National University of Juridical Sciences in the eastern city of Kolkata. Bayer got India patent for Nexavar in 2008.
http://online.wsj.com/news/articles/SB10001424127887324178904578340013954624212#printMode

Popular Now
ARTICLES

What's This?

1 2 3 4 5

Chinese Planes Sight Objects in Indian Ocean

U.S. Scurries to Shore Up Spying on Russia

U.S., U.K. Providing Data on Plane Search

The Secret About Online Ad Traffic

Taiwan Police Evict Protesters From Cabinet Building

VIDEO

Opinion: Missing George W. Bush Yet?

1/3

24/3/2014

India Rejects Bayer's Nexavar Plea - WSJ.com

Last year, the patent authority noted that Bayer's branded drug Nexavar sells for $5,181, or 284,428 rupees, for a month's supply. Natco Pharma, the generics competitor which brought the case to the patent authority, sought to sell a month's supply of the generic version at $160. The patent body allowed Natco to legally make and sell the low-cost version of Bayer's drug on the condition that it pay a royalty of about 6% of the net sales from the drug to the German company. The appellate board Monday ordered Natco to pay 7% of its net sales from the drug to Bayer. Medecins Sans Frontieres said it was "relieved" with the decision by the board to uphold India's first compulsory license. "Most importantly, the decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price," said Leena Menghaney, India manager of its advocacy program which pushes for greater access to lifesaving medicines. "We hope that, in the near future, compulsory licenses will be issued for the newest drugs to treat HIV and affordable generic versions will be available not only in India, but in the rest of the developing world," Ms. Menghaney added. To get patent protection under India's laws, companies need to prove that new versions of their products are therapeutically more beneficial than earlier versions on which patents have expired. Under this rule, India had refused to patent Swiss Novartis SA NOVN.VX -0.62% 's cancer drug Glivec. Novartis has taken the patent battle to India's Supreme Court, which is expected to give its final order on the case shortly. An Indian government panel late last month published a set of proposals to control the prices of patented drugs. If implemented, these guidelines could lead to multinational drug companies being forced to sell some medicines at a third of their current prices.
Email Print Sav e 0 Comments Order Reprints

2 3 4 5

Opinion: College Women Won't Marry Himbos

CCTV Footage Shows Gunmen in Kabul Hotel Attack

Pro-Russian Forces Storm Ukrainian Air Force Base

China Releases New Satellite Image of Object

Content From Sponsors

Can We Learn from History?
Ricoh

What's This?

Why File Sync and Share Apps like Box and Dropbox Werent Conceived for the Enterprise
CollaboristaBlog

WSJ In-Depth

Cook Admits Apple Blew the Call on the iPhone 5C

CIO

Are Firms Entitled to Religious Protections?

City vs. Country: How Where We Live Deepens a Political Divide

Baby Bust Hits Developing World

DKNY Girl Dallas Shaws Business Advice: Just Do Something
Fox Business

How Putin Parried Obama's Overtures

Senate Minority Leader Campaigns on Clout

Iraqi Officer T akes Dark T urn to al Qaeda

SPONSORED LINKS

2014 Crossover SUVs Practice Stock Trading Top Dividend Funds Best Stocks To Buy Best CD Rates

10 Best Mutual Funds Best Culinary Schools Best Traditional IRA Big-Data Analytics Hot Penny Stocks To Buy

Add a Comment

JOURNAL COMMUNITY

http://online.wsj.com/news/articles/SB10001424127887324178904578340013954624212#printMode

2/3

24/3/2014

India Rejects Bayer's Nexavar Plea - WSJ.com

Com m unity rules

To add a comment please

Log in

Create an Account
Your real name is required for commenting.

Track replies to my comment

CLEAR POST

Wall Street Facebook Journal Twitter LinkedIn FourSquare Google+ Y ouTube Podcasts RSS Feed

AppStore

Subscribe / Login

Back to Top

Customer Service
Customer Center Contact Us WSJ Weekend Contact Directory Corrections

Policy
Privacy Policy Cookie Policy Data Policy Copyright Policy Updated : Subscriber Agreement & Terms of Use Your Ad Choices

Ads
Advertise Place a Classified Ad Sell Your Home Sell Your Business Commercial Real Estate Ads Recruitment & Career Ads Franchising Advertise Locally

Tools & Features

Apps Emails & Alerts Graphics & Photos Columns Topics Guides Portfolio Old Portfolio

More
Register for Free Reprints E-books Content Partnerships Conferences Academic Partnerships Leadership Program Events in Asia Mobile Site News Archive

Jobs at WSJ

Copyright 2014 Dow Jones & Company, Inc. All Rights Reserved.

Copyright 2013 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com

http://online.wsj.com/news/articles/SB10001424127887324178904578340013954624212#printMode

3/3